Development of a first-in-class therapeutic to treat epithelial ovarian cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210472
- Recipient
-
Microquin LTD UEI UVZ4XT6GKZ36
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $248,250
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Cambridge, MA 02139, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $248,250 Project Grant to Microquin LTD on June 1, 2022 to support the development of a first-in-class therapeutic to treat epithelial ovarian cancer. The work will be performed in Cambridge, MA from June 1, 2022 through May 31, 2023.
The grant is being funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative medical solutions for battlefield injuries and other health issues. Microquin LTD will leverage the grant funding to advance its efforts to develop a novel therapeutic agent to treat epithelial ovarian cancer, addressing an important medical need consistent with the program's focus on impactful biomedical research.
Quick answers
Who received award W81XWH2210472?
W81XWH2210472 was awarded to Microquin LTD by Medical Command (Department of the Army) on June 1, 2022.
How much is award W81XWH2210472 worth?
$248,250 has been obligated on W81XWH2210472.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award